Summary
Hanmi Pharmaceutical has reached an important commercial milestone.
On October 7, Korea's Ministry of Food and Drug Safety approved Eppe, the company's independently developed GLP-1 obesity treatment containing efpeglenatide.
It is Korea's 45th domestically developed new drug and the first locally developed GLP-1 treatment approved for obesity.
The decision moves Hanmi from clinical development toward direct participation in a market dominated by imported medicines.
But the stock market delivered a different message.
Hanmi shares fell 10.02% to KRW 480,500 on October 8, despite the approval.
The decline suggests investors had already priced in much of the regulatory success.
It also raises a more important question.
What comes after approval?
Hanmi plans to manufacture Eppe at its Pyeongtaek biopharmaceutical facility and compete through domestic supply, differentiated clinical evidence and accessible pricing.
The company has previously outlined an ambition to develop Eppe into a product with annual domestic sales exceeding KRW 100 billion.
That target is not yet supported by commercial prescription data.
Meanwhile, Hanmi's existing pharmaceutical business remains profitable.
The company generated record 2025 revenue of KRW 1.55 trillion and operating profit of KRW 257.8 billion.
H1 2026 operating profit increased to KRW 184.7 billion, supported by domestic pharmaceutical sales and licensing income.
That gives Hanmi a stronger financial foundation than many development-stage biotech companies.
But it also makes the next earnings question more demanding.
Can Eppe become a recurring pharmaceutical franchise rather than another clinical milestone whose value is largely reflected in the share price?
Key Takeaways
- ✓ On October 7, the MFDS approved Eppe, making it Korea's first domestically developed GLP-1 obesity treatment.
- ✓ The approved indication covers eligible adults with obesity or overweight without diabetes. The authorization includes five dosage strengths.
- ✓ In a 40-week interim Phase 3 analysis involving 448 Korean patients, efpeglenatide achieved mean weight reduction of 9.75%, compared with 0.95% for placebo.
- ✓ Hanmi will manufacture Eppe domestically at its Pyeongtaek biopharmaceutical facility. Final commercial pricing and sustained prescription demand remain unproven.
- ✓ Hanmi generated KRW 1.55 trillion in revenue and KRW 257.8 billion in operating profit in 2025. H1 2026 operating profit reached KRW 184.7 billion, partly supported by licensing income.
- ✓ Shares declined 10.02% on October 8 despite the regulatory approval, reinforcing the importance of separating anticipated milestones from incremental earnings.
- ✓ The latest three-month brokerage consensus target of KRW 592,667 implies approximately 23.3% upside from the October 8 closing price.
What Happened
Hanmi Pharmaceutical received regulatory approval for Eppe on October 7.
The treatment is based on efpeglenatide, a long-acting GLP-1 receptor agonist developed using Hanmi’s LAPSCOVERY platform.
The MFDS approved five strengths of the injectable medicine.
The indication covers chronic weight management, alongside diet and exercise, for adults without diabetes who meet defined obesity or overweight criteria.
The approval followed a Korean Phase 3 clinical program.
In the previously disclosed 40-week interim analysis, 448 participants were evaluated.
Patients receiving efpeglenatide achieved average weight reduction of 9.75%.
Approximately 49.5% achieved weight loss of at least 10%.
The results provide clinical support for commercialization.
They should not be interpreted as evidence of superior efficacy over Wegovy or Mounjaro, because the disclosed study was not a direct head-to-head comparison.
Hanmi is preparing a domestic launch, potentially as early as October.
The company plans to manufacture the medicine at its Pyeongtaek biopharmaceutical plant.
Management has emphasized the potential advantages of domestic manufacturing, stable supply and more accessible pricing.
However, the final launch price has not been formally disclosed.
The market response was immediate.
Hanmi shares closed at KRW 480,500 on October 8, down 10.02%.
The approval removed a major regulatory uncertainty.
But it did not immediately establish how much revenue and profit the new treatment would generate.
Why It Matters
Regulatory approval changes the nature of Hanmi’s investment case.
Before approval, Eppe’s value depended primarily on clinical and regulatory probabilities.
After approval, it increasingly depends on commercial execution.
The earnings transmission is:
Regulatory Approval
→ Product Launch
→ Physician Prescriptions
→ Patient Adoption
→ Repeat Treatment
→ Revenue
→ Operating Profit
That transition is important in obesity treatment.
These medicines are intended for ongoing weight management.
Commercial value therefore depends on more than the number of patients trying a drug for the first time.
Treatment persistence matters.
Patient affordability matters.
And physicians must have confidence in efficacy, tolerability and long-term clinical management.
Hanmi has a potentially useful advantage.
It already operates an established domestic prescription-drug business and maintains broad relationships with Korean healthcare providers.
That infrastructure could support a faster commercial rollout than a smaller biotechnology company could achieve independently.
Domestic manufacturing may also strengthen supply reliability.
But those advantages must translate into prescription volume.
The critical indicators will be actual launch pricing, physician adoption, repeat prescriptions and profitability after manufacturing and marketing costs.
Eppe has crossed the regulatory threshold.
The commercial threshold is next.
Hanmi's achievement is meaningful.
But the investment opportunity is not simply that Korea now has a locally developed GLP-1 drug.
The more important development is that Hanmi can attempt to monetize its own obesity medicine through an existing commercial pharmaceutical platform.
That distinguishes the company from biotech developers whose economics depend primarily on licensing agreements.
Eppe could create direct product revenue.
It could also deepen Hanmi's presence in metabolic disease treatment.
However, Korea Alpha sees two limitations.
The first is competition.
Eppe is entering a market where Wegovy and Mounjaro already have established recognition and clinical adoption.
The second is valuation.
The October 8 share-price decline shows that approval was not enough to sustain the market's previous expectations.
Investors now need evidence that the medicine can compete commercially.
Pricing alone will not determine success.
The combination of affordability, clinical confidence, availability and treatment persistence will be more important.
Hanmi's existing profitability gives the company financial flexibility to develop that business.
The next proof point is whether Eppe can create recurring earnings that are material at the consolidated level.